MCUJF-"Why would sales of Aggrestat double this late in the game? Aggrestat has been on the market since 1996, and there are several newer and better options for platelet inhibition."
Exactly, but the company has taken this product and doubled sales in the last year. Each new double in sales will be more and more difficult, but not an insurmountable task given the low bar of $30 million/year given the size of the emergency anticoagulant market. The fundamental question(s) are more likely related to where AGGRASTAT is being sold, pricing, and, how does one put it, " easing market acceptance" of a cost/benefit if this is taking new customers because it's price advantage is greater than the inferiority issues. From what I've read (and it's admittedly a cursory review), AGGRASTAT has acceptable costs vis a vis side effects and efficacy limits.
I know of many settings in mental health (my bailiwick) where insurance medication benefit is a cost issue and inferior medications that are cheaper are the only covered meds.
